Your browser doesn't support javascript.
loading
Effect of kurarinol on peripheral blood CTL surface PD-1 expression of patients with chronic hepatitis B / 中华实验和临床病毒学杂志
Article de Zh | WPRIM | ID: wpr-305013
Bibliothèque responsable: WPRO
ABSTRACT
<p><b>OBJECTIVE</b>To explore the anti-viral mechanism of kurarinol through studying its influence on cytotoxic T lymphocyte (CTL) surface program death receptor-1 (PD-1) expression of patients with chronic hepatitis B (CHB).</p><p><b>METHODS</b>69 cases of CHB, HBV DNA > or = 10(4) copies/ml, HBeAg positive, human leukocyte antigen (HLA)-A2 positive, alanine aminotransferase (ALT) > 2 x upper limit of normal value(ULN).69 cases were randomly divided into two groups:34 cases in treatment group,600 mg of kurarinol glucose injection was used for intravenous dripping, once a day, one month later, 200 mg of kurarinol capsule was used orally,three times a day and 200 mg of silybin meglumine tablet was used orally, three times a day. 35 cases in control group, only silibin meglumine tablet was used, method and dosage were the same as those of treatment group. Three months later, their peripheral blood HBV specific CTL surface PD-1 expression, non-specific CTL surface PD-1 expression and level of HBV specific CTL,HBV DNA and HBeAg negative rate and liver functions were analyzed and compared.</p><p><b>RESULTS</b>3 months after treatment, peripheral blood HBV specific CTL surface PD-1 expression of the treatment group decreased compared with that before treatment (t = 2.39, P < 0.05), it also decreased compared with that of the control group 3 months after treatment (t = 2.26, P < 0.05), HBV specific CTL increased compared with that before treatment( t = 3.01, P < 0.01), it also increased compared with that of the control group after treatment (t = 2.65, P < 0.05). There was no significant difference of non-specific CTL surface PD-1 expression compared with that before treatment (P > 0.05), and there was no significant difference compared with that of the control group after treatment (P > 0.05). HBV DNA of 11 cases (32.5%) turned negative ( HBV DNA < 500 copies/ ml), higher than that of the control group after treatment (2 cases, 5.71%) chi2 = 7.99, P < 0.01, HBeAg of 9 cases (26.47%) turned negative, higher than that of the control group after treatment (1 case, 2.86%), chi2 = 7.75, P < 0.01.</p><p><b>CONCLUSION</b>Kurarinol can increase level of HBV specific CTL by down-regulating peripheral blood HBV specific CTL surface PD-1 expression of CHB patients, which may be one of the possible mechanisms that kurarinol can remove or inhibit HBV of CHB patients.</p>
Sujet(s)
Texte intégral: 1 Indice: WPRIM Sujet Principal: Physiologie / Virologie / Flavonoïdes / Médicaments issus de plantes chinoises / Lymphocytes T cytotoxiques / Expression des gènes / Virus de l'hépatite B / Résultat thérapeutique / Hépatite B chronique / Traitement médicamenteux Limites du sujet: Adult / Humans / Male langue: Zh Texte intégral: Chinese Journal of Experimental and Clinical Virology Année: 2012 Type: Article
Texte intégral: 1 Indice: WPRIM Sujet Principal: Physiologie / Virologie / Flavonoïdes / Médicaments issus de plantes chinoises / Lymphocytes T cytotoxiques / Expression des gènes / Virus de l'hépatite B / Résultat thérapeutique / Hépatite B chronique / Traitement médicamenteux Limites du sujet: Adult / Humans / Male langue: Zh Texte intégral: Chinese Journal of Experimental and Clinical Virology Année: 2012 Type: Article